Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
P/E ratio for Lipella Pharmaceuticals Inc. (LIPO)
P/E ratio as of 2023: -10.61
According to Lipella Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.61. At the end of 2022 the company had a P/E ratio of -55.40.
P/E ratio history for Lipella Pharmaceuticals Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -10.61 |
| 2022 | -55.40 |
| 2021 | -17.64 |
| 2020 | -492.64 |
| 2019 | -529.30 |